IGF2BP1 and prostate cancer: However, by integrating the GTEx and TCGA datasets, IGF2BP1-3 can be re-expressed in a broad range of cancer types and diverse cancer cell lines (Figures 1D–I), Specifically, IGF2BP1 expression was significantly higher in most of the tumor tissues (n = 30/34) and significantly lower in prostate cancer (PRAD) (P < 0.05) than that in normal tissues (Figure 1D); IGF2BP1 expression was similar between rectal cancer (READ) (P > 0.05), testicular cancer (TGCT) (P > 0.05), and pheochromocytoma & paraganglioma (PCPG) (P > 0.05) tumor tissues and normal tissues.